Skip to main content
SpringerLink
Log in

HTLV-III antibody prevalence among young delinquent drug abusers in long-term residential treatment at a north-German drug clinic

  • Originalien
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

To date, long-term intravenous drug users studied at regional European centers of illicit drug use have had a high number of LAV/HTLV-III infections. Among 200 patients remanded by court or referred from prison to a special clinic in northern Germany for young delinquent drug abusers, 26 (17%) of 157 IV drug abusers were HTLV-III seropositive. With 40% seropositive, female patients showed a significantly higher prevalence of HTLV-III infection than males. The results of longitudinal serological, immunological, and clinical observations over periods of 12 months and 2–3 years indicate that under conditions of continuous medical surveillance, sound preventive counseling, and steady therapeutic care during long-term coeducative residential treatment of drug abusers, neither detectable HTLV-III transmission nor definite progression of HTLV-III induced impairment of immune regulatory functions must ensue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

AIDS:

acquired immune deficiency syndrome

CDC:

Centers for Disease Control

HTLV-III:

human T-lymphotropic virus type III

IV:

intravenous

LAV:

lymphadenopathy-associated virus

References

  1. Angarano G, Pastore G, Monno L, Santantonio T, Zuchena N, Schiraldi O (1985) Rapid spread of HTLV-III infection among drug addicts in Italy. Lancet II:1302

    Google Scholar 

  2. Curran JW, Meade Morgan W, Hardy AM, Jaffe HW, Darrow WW, Dowdle WR (1985) The epidemiology of AIDS — current status and future prospects. Science 229:1552

    Google Scholar 

  3. Ferroni P, Geroldi D, Galli C, Zanetti AR, Carguel A (1985) HTLV-III antibody among Italian drug addicts. Lancet II:52–53

    Google Scholar 

  4. Fuchs D, Blecha HG, Deinhardt F, Dierich MP, Goebel FD, Hengster P, Hinterhuber H, Schoenitzer D, Traill K, Wachter H (1985) High frequency of HTLV-III antibodies among heterosexual intravenous drug abusers in the Austrian Tyrol. Lancet I:1506

    Google Scholar 

  5. Ginzburg, HM (1985) Intravenous drug users and the acquired immune deficiency syndrome. Public Health Rep 99:206–212

    Google Scholar 

  6. Hunsmann G, Schneider J, Bayer H, Kurth R, Werner A, Brede HD, Erfle V, Mellert W. Brodt HR, Bergmann L, Helm I, Scherrer I, Krenz W, Berthold H, Wernet P, Schneider EM, Schimpf K, Egli U, Bienzle U, Schmitz H, Kern P, Krüger G, Rasokat H, Lechler E. Seifried E, Hellstern P, Schneider W, Holzer E, Goebel FD, Hehlmann R (1985) Seroepidemiology of HTLV-III (LAV) in the Federal Republic of Germany. Klin Wochenschr 63:233–235

    PubMed  Google Scholar 

  7. Joller-Jemelka HI, Wilhelm U, Steffen R, Grob PJ (1985) Virale Hepatitis und AIDS-assoziierte HTLV-III/LAV-Virusinfektionen bei Drogenabhängigen. Schweiz Med Wochenschr 115 (33):1114–1119

    PubMed  Google Scholar 

  8. Mortimer PP, Vandervelde EM, Jesson WJ, Pereira MS, Burkhardt F (1985) HTLV-III antibody in Swiss and English intravenous drug abusers. Lancet II:449–550

    Google Scholar 

  9. Peutherer JF, Edmond E, Simmonds P, Dickson PD, Bath GE (1985) HTLV-III antibody in Edinburgh drug addicts. Lancet II:1129–1130

    Google Scholar 

  10. Rodrigo JM, Serra MA, Aguilar E, Del Olmo JA, Gimeno V, Aparisi L (1985) HTLV-III antibodies in drug addicts Spain. Lancet II:156–157

    Google Scholar 

  11. Schüpbach J, Vogt M, Bhushan R, Lüthy R, Haller O, Joller H, Ferber T, Büchner S, Schuppli R, Schädelin J, Hirschel B, Cruchand A, Stroun J, Frei P, Glauser MP (1985) Prävalenz von Antikörpern gegen HTLV-III in verschiedenen Regionen der Schweiz. Schweiz Med Wochenschr 115 (30):1048–1054

    PubMed  Google Scholar 

  12. Spira TJ, Des Jarlais DC, Marmor M, Yancovitz S, Friedman S, Garber J, Cohen H, Cabradilla, Kalyanaraman VC (1984) Prevalence of antibody to lymphadenopathy-associated virus among drug-detoxification patients in New York. N Engl J Med 7:467–468

    Google Scholar 

  13. Tirelli U, Vaccher E, Carbone A, DePaoli P, Santini GF, Monfardini S (1985) HTLV-III antibody in prostitutes. Lancet II:1424

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Niedersächsisches Landeskrankenhaus Brauel, Germany

    G. Paschelke, G. Altvater-Kremer, W. D. Meyer & H. Kremer

Authors
  1. G. Paschelke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Altvater-Kremer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W. D. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Kremer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paschelke, G., Altvater-Kremer, G., Meyer, W.D. et al. HTLV-III antibody prevalence among young delinquent drug abusers in long-term residential treatment at a north-German drug clinic. Klin Wochenschr 65, 22–26 (1987). https://doi.org/10.1007/BF01785522

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01785522

Key words

Search

Navigation